Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.51 USD | 0.00% | -6.76% | -19.61% |
Financials (USD)
Sales 2024 * | 307K | Sales 2025 * | 3.11M | Capitalization | 1.1B |
---|---|---|---|---|---|
Net income 2024 * | -266M | Net income 2025 * | -293M | EV / Sales 2024 * | 2,218 x |
Net cash position 2024 * | 418M | Net cash position 2025 * | 587M | EV / Sales 2025 * | 165 x |
P/E ratio 2024 * |
-3.98
x | P/E ratio 2025 * |
-4.03
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
Latest transcript on Viridian Therapeutics, Inc.
1 week | -6.76% | ||
Current month | -6.41% | ||
1 month | -13.19% | ||
3 months | -21.80% | ||
6 months | +15.50% | ||
Current year | -19.61% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 23-10-29 | |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 227 M€ | +5.31% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 735 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 17.51 | 0.00% | 1,010,508 |
24-03-27 | 17.51 | +0.81% | 707,739 |
24-03-26 | 17.37 | -1.03% | 621,252 |
24-03-25 | 17.55 | -2.55% | 921,860 |
24-03-22 | 18.01 | -4.10% | 849,852 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.61% | 1.1B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |